Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple
sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 …

Background: There is no consensus method for determining progression of disability in
patients with multiple sclerosis (MS) when each patient has had only a single assessment in …

Multiple sclerosis is a chronic, often disabling, disease of the central nervous system
affecting more than 1 in 1,000 people in most western countries. The inflammatory lesions …

Common risk factors for psychiatric and other brain disorders are likely to converge on
biological pathways influencing the development and maintenance of brain structure and …

Abstract/summary Chronic fatigue and major depression (MDD)-like symptoms are common
manifestations of multiple sclerosis (MS), both with huge impact on quality of life. Depression …

The human leukocyte antigen (HLA) haplotype DRB1* 15: 01 is the major risk factor for
multiple sclerosis (MS). Here, we find that DRB1* 15: 01 is hypomethylated and …

Multiple sclerosis (MS) is an inflammatory CNS disease with a substantial genetic
component, originally mapped to only the human leukocyte antigen (HLA) region. In the last …

Background Driving ability is a key function for the majority of patients with multiple sclerosis
(MS) to help maintain daily interactions. Both physical and cognitive disability, as well as …

Multiple sclerosis is a complex neurological disease, with∼ 20% of risk heritability
attributable to common genetic variants, including> 230 identified by genome-wide …

Objective: To explore the relationship between fatigue, sociodemographic and clinical
variables in a population of patients with multiple sclerosis (MS). Rationale: There is a need …